- The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE:LLY) rheumatoid arthritis drug for an initial portfolio of preferred medications to treat COVID-19, reports Reuters.
- The selection of drugs is part of the E.U. Strategy on COVID-19 therapeutics, launched in May.
- Top picks include Eli Lilly - Incyte Corporation's (NASDAQ:INCY) Olumiant for hospitalized COVID-19 patients on oxygen, as well as new antibody drugs for early-stage disease from Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Eli Lilly, Celltrion, and GlaxoSmithKline plc (NYSE:GSK) - Vir Biotechnology Inc (NASDAQ:VIR).
- The Commission reiterated it would draw up a portfolio of at least ten potential COVID-19 therapeutics.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
